Johns Hopkins University

Cyvax, Inc.

Richard Markham

Eileen Geoghegan

Bira Arya

Kristen V Khanna

James Gordy

Provided herein, in some embodiments, are methods and composition for treating cancer in a subject. The methods may include administering to the subject a nucleic acid encoding MIP3&#x3b1; fused to a cancer antigen, administering to the subject a CpG oligodeoxynucleotide, administering to the subject interferon alpha (IFN&#x3b1;), and administering to the subject 5-aza-2'-deoxycytidine (Aza), in effective amounts to treat the cancer.

Methods and compositions for treating cancer

The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked toexotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.

Antimicrobial compositions comprising single domain antibodies andexotoxin

Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin

Disclosed herein are DNA-based vaccines against amyloid &#x3b2; peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid &#x3b2; peptides, such as amino acids 1-11 of A&#x3b2;, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.

Vaccines for protection from and treatment of alzheimer's disease

Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3&#x3b1;, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.

Methods and compositions for treating malaria

Methods, compositions and articles for blocking transepithelial transmission of HIV with ICAM-1 angonist/antagonists are provided. The ICAM-1 agonist/antagonists block viral transmission at the site of exposure to the virus. Blocking viral transmission does not require blocking the binding of ICAM-1 to LFA-1. The ICAM-1 agonist/antagonists may be applied to mucosal surfaces, on or in contraceptive devices or in oral solutions such as breast milk supplements and infant formula.

Growing community of inventors

Columbia, MD, United States of America

Richard Markham